Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954

NCT03277274 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT03277274
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03277274 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Non-Randomized, Open-Label Trial to Evaluate the Effect of Hepatic Impairment on the Single Dose Pharmacokinetics of Intravenous TAK-954
Lead sponsor
Takeda
Phase
Phase 1
Overall status
Completed
Start date
November 9, 2017
Completion date
September 10, 2018
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment